[CLS] O
22 B
- I
oxacalcitriol I
suppresses O
secondary O
hyperparathyroidism O
without O
inducing O
low O
bone O
turnover O
in O
dogs O
with O
renal O
failure O
. O
[SEP] O

[CLS] O
In O
long O
- O
standing O
secondary O
hyperparathyroidism O
, O
OCT B
( O
0 O
. O
03 O
microg O
/ O
kg O
) O
stabilized O
serum O
PTH O
levels O
during O
the O
first O
months O
. O
[SEP] O

[CLS] O
The O
patient O
was O
admitted O
with O
a O
pulmonary O
- O
renal O
syndrome O
with O
hemoptysis O
, O
rapidly O
progressive O
renal O
failure O
, O
and O
hypoxemia O
that O
required O
mechanical O
ventilation O
in O
the O
intensive O
care O
unit O
. O
[SEP] O

[CLS] O
Urine O
N O
- O
acetyl O
- O
beta O
- O
D O
- O
glucosaminidase O
- O
- O
a O
marker O
of O
tubular O
damage O
? O
[SEP] O

[CLS] O
CONCLUSIONS O
: O
This O
animal O
model O
demonstrates O
that O
an O
increase O
in O
lysosomal O
turnover O
and O
hence O
urine O
NAG O
activity O
, O
occurs O
when O
increased O
protein O
is O
presented O
to O
the O
tubular O
cells O
. O
[SEP] O

[CLS] O
We O
recommend O
that O
hyperbaric O
lignocaine B
should O
be O
administered O
in O
concentrations O
not O
greater O
than O
2 O
% O
and O
at O
a O
total O
dose O
preferably O
not O
exceeding O
60 O
mg O
. O
[SEP] O

[CLS] O
OBJECTIVES O
: O
To O
assess O
changes O
induced O
by O
lithium B
maintenance O
therapy O
on O
the O
incidence O
of O
thyroid O
, O
parathyroid O
and O
ion O
alterations O
. O
[SEP] O

[CLS] O
Women O
over O
60 O
years O
of O
age O
were O
more O
often O
affected O
by O
hypothyroidism O
than O
women O
under O
60 O
years O
of O
age O
( O
34 O
. O
6 O
% O
versus O
31 O
. O
9 O
% O
) O
. O
[SEP] O

[CLS] O
Platelet O
function O
is O
impaired O
by O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
with O
prominent O
anti O
- O
inflammatory O
properties O
. O
[SEP] O

[CLS] O
Ketoprofen B
but O
not O
acetaminophen B
impaired O
platelet O
function O
in O
patients O
with O
SAH O
. O
[SEP] O

[CLS] O
The O
study O
also O
revealed O
significant O
inhibition O
of O
NOS O
enzymatic O
activity O
by O
lead B
in O
cell O
- O
free O
preparations O
. O
[SEP] O

[CLS] O
Headache O
was O
more O
severe O
in O
migraineurs O
than O
in O
the O
controls O
during O
and O
immediately O
after O
GTN B
infusion O
( O
p O
= O
0 O
. O
037 O
) O
as O
well O
as O
during O
the O
following O
11 O
h O
( O
p O
= O
0 O
. O
008 O
) O
. O
[SEP] O

[CLS] O
BACKGROUND O
: O
Although O
angiotensin B
- O
converting O
enzyme O
inhibitor O
therapy O
reduces O
mortality O
rates O
in O
patients O
with O
congestive O
heart O
failure O
( O
CHF O
) O
, O
it O
may O
also O
cause O
decreased O
renal O
function O
. O
[SEP] O

[CLS] O
Diuretic B
therapy O
was O
likewise O
associated O
with O
a O
greater O
risk O
of O
decreased O
renal O
function O
in O
the O
enalapril B
group O
( O
RR O
1 O
. O
89 O
, O
95 O
% O
CI O
1 O
. O
70 O
- O
2 O
. O
08 O
) O
than O
in O
the O
placebo O
group O
( O
RR O
1 O
. O
35 O
, O
95 O
% O
CI O
1 O
. O
09 O
- O
1 O
. O
66 O
) O
. O
[SEP] O

[CLS] O
Acute O
confusion O
induced O
by O
acetazolamide B
is O
a O
well O
known O
adverse O
drug O
reaction O
in O
patients O
with O
renal O
impairment O
. O
[SEP] O

[CLS] O
Conversion O
was O
early O
in O
29 O
patients O
( O
41 O
. O
4 O
% O
) O
and O
late O
in O
41 O
( O
58 O
. O
6 O
% O
) O
. O
[SEP] O

[CLS] O
Iridocyclitis O
was O
seen O
most O
frequently O
in O
young O
female O
patients O
( O
0 O
to O
4 O
years O
) O
with O
the O
monoarticular O
or O
pauciatricular O
form O
of O
the O
arthritis O
. O
[SEP] O

[CLS] O
Typical O
keratoconjunctivitis O
sicca O
developed O
in O
three O
of O
the O
uveitis O
cases O
. O
[SEP] O

[CLS] O
Finally O
, O
to O
show O
that O
the O
bladder O
is O
essential O
for O
the O
CP B
- O
induced O
behavioral O
modifications O
, O
female O
rats O
also O
received O
CP B
at O
doses O
of O
200 O
mg O
. O
/ O
kg O
. O
[SEP] O

[CLS] O
i O
. O
p O
. O
, O
with O
the O
same O
maximal O
levels O
. O
[SEP] O

[CLS] O
Rate O
of O
body O
weight O
gain O
was O
depressed O
in O
the O
P100 O
, O
FR O
, O
and O
P10 O
groups O
compared O
with O
the O
S O
group O
. O
[SEP] O

[CLS] O
Apomorphine B
: O
an O
underutilized O
therapy O
for O
Parkinson O
' O
s O
disease O
. O
[SEP] O

[CLS] O
OBJECTIVE O
: O
The O
pharmacological O
response O
to O
drugs O
that O
act O
on O
the O
cholinergic O
system O
of O
the O
iris O
has O
been O
used O
to O
predict O
deficits O
in O
central O
cholinergic O
functioning O
due O
to O
diseases O
such O
as O
Alzheimer O
' O
s O
disease O
, O
yet O
correlations O
between O
central O
and O
peripheral O
responses O
have O
not O
been O
properly O
studied O
. O
[SEP] O

[CLS] O
In O
2 O
separate O
sessions O
, O
a O
single O
dose O
of O
scopolamine B
( O
0 O
. O
5 O
mg O
, O
intravenously O
) O
or O
placebo O
was O
administered O
, O
and O
the O
effects O
on O
word O
recall O
were O
measured O
using O
the O
Buschke O
Selective O
Reminding O
Test O
over O
2 O
hours O
. O
[SEP] O

[CLS] O
By O
using O
a O
placebo O
- O
controlled O
, O
two O
- O
way O
factorial O
design O
, O
tolerance O
to O
cold O
- O
pressor O
( O
CP O
) O
pain O
was O
examined O
, O
both O
before O
and O
after O
oral O
administration O
of O
therapeutic O
doses O
of O
common O
opioid O
( O
hydromorphone B
2 O
mg O
) O
and O
nonsteroidal O
anti O
- O
inflammatory O
( O
ketorolac B
10 O
mg O
) O
analgesic O
agents O
. O
[SEP] O

